Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

European Journal of Haematology

Volumn 80, Issue 1, 2008, Pages 31-36

  Tosi, Patrizia ^a,b   Terragna, Carolina ^b   Testoni, Nicoletta ^b   Zamagni, Elena ^b   Renzulli, Matteo ^b   Tacchetti, Paola ^b   Montanari, Elena ^b   Perrone, Giulia ^b   Ceccolini, Michela ^b   Brioli, Annamaria ^b   Pallotti, Maria C ^b   Tura, Sante ^b   Baccarani, Michele ^b   Cavo, Michele ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bone disease; Magnetic resonance imaging; Multiple myeloma; t(4; 14)

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BONE DISEASE; BONE REMODELING; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FEMALE; FUSION GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; SCORING SYSTEM; SEX RATIO; STATISTICAL SIGNIFICANCE; VERTEBRA DISLOCATION; X RAY;

ADULT; AGED; BONE DISEASES; BONE RESORPTION; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

EID: 37249023709     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00974.x     Document Type: Article

References (34)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997 336 : 1657 64.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004 351 : 60 73.
3. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple mieloma. Oncogene 2001 20 : 5611 22.
4. Fonseca R, Debes-Marun CS, Pichen FB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003 102 : 2562 7.
5. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006 20 : 807 13.
6. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuhel WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996 88 : 674 81.
7. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004 64 : 1546 58.
8. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in multiple myeloma. Blood 2003 101 : 4569 75.
9. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous stem cell transplantation. Blood 2003 102 : 1588 94.
10. Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C, Stewart AK. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005 23 : 7069 73.
11. Cavo M, Terragna C, Renzulli M, et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 2006 24 : e4 5.
12. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcript. Blood 1998 92 : 3025 34.
13. Keats JJ, Maxwell C, Taylor BJ, et al. Overexpression of transcript originating from MMSET locus characterizes all t(4;14)(p16;q32) - positive myeloma patients. Blood 2005 105 : 4060 9.
14. Robbiani DF, Chesi M, Bergsagel PL. Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004 351 : 197 8.
15. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004 89 : 826 31.
16. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 106 : 35 9.
17. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendoff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated levels of S-ICTP and U-NTX are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003 120 : 235 42.
18. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997 90 : 2127 47.
19. Small E, Smith MR, Seaman JJ, Petrone S, Ortu Kawalski M. Combined analysis of two multicenter, randomized placebo controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003 23 : 4277 84.
20. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minsielle S, Bataille R. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood 2002 99 : 2185 91.
21. Griepp PR, San Miguel J, Durie BM, et al. International staging system for multiple myeloma. J Clin Oncol 2005 23 : 3412 20.
22. Tosi P, Zamagni E, Cellini C, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006 76 : 399 404.
23. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendoff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004 89 : 567 77.
24. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implication of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and 17p13 in myeloma patients treated with high-dose therapy. Blood 2005 106 : 2837 40.
25. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myelome. Blood 2007 109 : 3489 95.
26. Cavo M, Testoni N, Terragna C, et al. Up-front thalidomide-dexamethasone (THAL) and double autologous transplantation (double Tx) for multiple myeloma: comparison with double Tx without added thalidomide and prognostic implication of chromosome 13 deletion and trnslocation t(4;14). Blood 2006 108 : 3081a.
27. Bahlis NJ, Mansoor A, Lategan JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood 2006 108 : 3557a.
28. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Res 2007 31 : 779 82.
29. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005 105 : 2941 8.
30. Nakazawa N, Nishida K, Tamuro A, et al. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies. Cancer Genet Cytogenet 2000 117 : 89 96.
31. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006 108 : 2020 8.
32. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Nes B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated myeloma patients. Br J Haematol 2000 109 : 24 9.
33. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003 102 : 1064 9.
34. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007 25 : 1121 8.